// App-Quantinova.ai

429 : An open-label, multicenter, phase IIIb study of patients with urinary tract carcinoma (UTC) (STRONG): Final analysis for fixed-dose durvalumab monotherapy (module A).

Researchers

Presenter

  • Guru Sonpavde

Principal Investigators

  • Yohann Loriot

  • Cora N. Sternberg

  • Jae-Lyun Lee

  • Aude Flechon

  • Guilhem Roubaud

  • Damien Pouessel

  • Vittorina Zagonel

  • Fabio Calabro

  • Giuseppe L. Banna

  • Sang Joon Shin

  • Francisco Emilio Vera Badillo

  • Thomas Powles

  • Eva Hellmis

  • Paulo Andre Palhares de Miranda

  • Ana Rita Lima

  • William Sawyer

  • Sebastien J. Hotte

Medical Centers

  • Dana-Farber Cancer Institute, Boston, MA

  • Institut Gustave Roussy, University of Paris Sud, Villejuif, France

  • Department of Cancer Medicine, Institut Gustave Roussy, Paris-Sud University, Villejuif, France

  • Weill Cornell Medicine, Division of Hematology & Medical Oncology, NewYork-Presbyterian Hospital, New York, NY

  • Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

  • Léon-Bérard Centre, Lyon, France

  • Institut Bergonie, Bordeaux, France

  • Institut Claudius Regaud, IUCT-Oncopole, CRCT, Inserm, Toulouse, France

  • Veneto Institute of Oncology IOV - IRCCS, Padua, Italy

  • San Camillo-Forlanini Hospital, Rome, Italy

  • Ospedale Cannizzaro, Catania, Italy

  • Yonsei University Severance Hospital, Seoul, South Korea

  • Department of Oncology, Queens University, Kingston, ON, Canada

  • Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

  • Urologicum Duisburg, Duisburg, Germany

  • AstraZeneca, Gaithersburg, MD

  • Juravinski Cancer Centre, Burlington, ON, Canada

Locations

  • United States

  • France

  • Republic of South Korea

  • Italy

  • Canada

  • United Kingdom

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Urinary tract cancers

Biomarkers

  • N/A

Drug/Treatment

  • Durvalumab

Outcome

  • N/A

Study Design

  • Fixed Dose

  • Open Label

  • Multicenteric

Phase

  • III

Study Id's

  • NCT03084471

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved